Documents

NCI-H69/LX20

96042332

Pricing and availability is not currently available.

biological source

human lung

growth mode

Aggregates in suspension

karyotype

Not specified

morphology

Not specified

products

Not specified

receptors

Not specified

application(s)

cell culture | mammalian: suitable

relevant disease(s)

cancer

shipped in

dry ice

storage temp.

−196°C

Related Categories

Cell Line Origin

Human Caucasian small cell lung carcinoma

Cell Line Description

The drug-resistant cell line NCI-H69/LX20 has been derived by exposure of the parent line, H69 (ECACC Number 91091802) to doxorubicin, also known as adriamycin. These multi drug resistant (MDR) cells have been found to be recognised by various anti-P-glycoprotein antibodies.

Application

Analysis of acquired drug resistance, study of small cell lung carcinoma, MDR studies.

Culture Medium

RPMI 1640 + 2mM Glutamine + 2μg/ml Doxorubicin + 10% Foetal Bovine Serum (FBS). ECACC has found that the following supplement will assist good growth of cells: sodium selenite 10nM, Insulin 250ng/ml, Transferrin 10ug/ml and sodium pyruvate 1mM.

Subculture Routine

Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage. Resuscitate into 9 ml of medium. Immediately after resuscitation perform a centrifugation ste

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

RIDADR

NONH for all modes of transport

Certificate of Analysis
Certificate of Origin

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.